Results 361 to 370 of about 264,257 (370)
Some of the next articles are maybe not open access.
Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning
Nature Medicine, 2002 Margaret, A., Shipp, Ken, N., Ross, P. Tamayo, Andrew, P., Weng, Jeffery, L., Kutok, riCardo, T. C., Aguiar, M. Gaasenbeek, Michael Angelo, Michael Reich, Geraldine, S., Pinkus, Tane, Ray, Koval, Kim, W., Last, Norton, T., Andrew Lister, J. Mesirov, Donna, Neuberg, Eric, Lander, Jon, C., Aster, Todd, R., Golub +41 moresemanticscholar +1 more sourceThe molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma.
Blood, 2003 K. Savage, S. Monti, J. Kutok, G. Cattoretti, D. Neuberg, L. de Leval, P. Kurtin, P. Dal Cin, C. Ladd, F. Feuerhake, R. Aguiar, Sigui Li, G. Salles, F. Berger, Wen Jing, G. Pinkus, T. Habermann, R. Dalla-Favera, N. Harris, J. Aster, T. Golub, M. Shipp +21 moresemanticscholar +1 more sourceDiffuse Large B-Cell Lymphomas
2010 De novo diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma worldwide, accounting for approximately 30–40% of adult non-Hodgkin lymphomas. It is defined as a diffuse proliferation of large neoplastic B lymphoid cells with a nuclear size equal to or exceeding that of a normal macrophage or more than twice the size of a normal lymphocyte ...openaire +1 more sourceCHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.
The Lancet Oncology, 2006 M. Pfreundschuh, L. Trümper, A. Osterborg, R. Pettengell, M. Trněný, K. Imrie, D. Ma, D. Gill, J. Walewski, P. Zinzani, R. Stahel, S. Kvaløy, O. Shpilberg, U. Jaeger, M. Hansen, T. Lehtinen, A. López-Guillermo, C. Corrado, A. Scheliga, N. Milpied, M. Mendila, M. Rashford, E. Kuhnt, M. Loeffler +23 moresemanticscholar +1 more source
